Actively Recruiting
Safety and Efficacy of Anlotinib in the Treatment of Recurrent Craniopharyngioma
Led by Nanfang Hospital, Southern Medical University · Updated on 2025-11-18
57
Participants Needed
1
Research Sites
155 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Primary Aim: To assess the objective remission rate (ORR) of patients with recurrent craniopharyngiomas treated with anlotinib . Secondary Aims: 1. To assess progression-free survival (PFS) and overall survival (OS) of patients with recurrent craniopharyngiomas treated with anlotinib. 2. To analyze the disease control rate (DCR) of the anlotinib treatment regimen in patients with recurrent craniopharyngiomas, including the proportion of patients in complete remission, partial remission and stable disease. 3. Monitor and evaluate the safety of anlotinib, especially the occurrence of drug-related adverse events (AEs) .
CONDITIONS
Official Title
Safety and Efficacy of Anlotinib in the Treatment of Recurrent Craniopharyngioma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18-75 years, all genders
- Recurrent craniopharyngioma confirmed by pathology and imaging
- Predominantly cystic or solid tumor recurrence
- Measurable tumor lesions according to RECIST criteria
- Karnofsky score of 70 or higher, expected survival of at least 3 months
- Laboratory test results within normal range or controlled
- Signed informed consent and willingness to participate
You will not qualify if you...
- Presence of other intracranial tumors or severe brain lesions
- Primary craniopharyngioma
- Severe uncontrolled heart, lung, kidney, or liver disease
- Children, pregnant or breastfeeding women
- Prior treatment with anlotinib
- Active infections including HIV, HBV, or HCV
- Contraindications to the investigational drug
- History of severe allergy to the investigational drug
- Psychiatric illnesses or cognitive impairments preventing understanding or follow-up
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Southern Medical University, Nanfang Hospital, Department of Neurosurgery
Guangzhou, Guangdong, China, 510515
Actively Recruiting
Research Team
J
Jun Pan, MD, Ph.D
CONTACT
Y
Yilamujiang Ainiwan, MD, Ph.D
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here